Background: This prospective, randomized controlled trial examined the effect of progressive muscle relaxation (PMR) training on anxiety and depression in patients with chronic breathing disorders receiving pulmonary rehabilitation (PR). Methods: Eighty-three subjects with chronic breathing disorders entering the 8-week PR program were randomly assigned to a standard care or intervention group. The standard program included 2 days per week of exercise, education and psychosocial support delivered by a multidisciplinary team. The intervention group received additional sessions of PMR training using a prerecorded tape for 25 min/week during weeks 2–8. Primary outcome measures were levels of anxiety and depression evaluated by the Hospital Anxiety and Depression Scale. Results: For anxiety, there was an overall significant improvement within each group over time (p < 0.0001). There was no statistically significant group-time interaction (p = 0.17) and no statistically significant difference between the groups (p = 0.22), despite lower scores for every time point in the PMR group. For depression, there was an overall significant improvement within each group over time (p < 0.0001). Although the difference between the groups (p = 0.09) and group-time interaction (p = 0.07) did not reach statistical significance, the results again favored the PMR group for weeks 5–8. Depression scores were lower for the PMR throughout weeks 1–8. Conclusions: PR is effective in reducing anxiety and depressive level in chronic lung patients. Our findings suggest that adding structured PMR training to a well-established PR program may not confer additional benefit in the further reduction of anxiety and depression in patients receiving PR.

Keywords:
Anxiety, Depression, Relaxation, Pulmonary rehabilitation, Chronic obstructive pulmonary disease
1.
Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA: Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005;127:1205–1211.
2.
Withers NJ, Rudkin ST, White RJ: Anxiety and depression in severe chronic obstructive pulmonary disease: the effects of pulmonary rehabilitation. J Cardiopulm Rehabil 1999;19:362–365.
3.
Mikkelsen RL, Middelboe T, Pisinger C, Stage KB: Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a review. Nord J Psychiatry 2004;58:65–70.
4.
Brenes GA: Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003;65:963–970.
5.
Stage KB, Middelboe T, Pisinger C: Depression and chronic obstructive pulmonary disease (COPD): impact on survival. Acta Psychiatr Scand 2005;111:320–323.
6.
Borson S, Claypoole K, McDonald GJ: Depression and chronic obstructive pulmonary disease: treatment trials. Semin Clin Neuropsychiatry 1998;3:115–130.
7.
Van Ede L, Yzermans CJ, Brouwer HJ: Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999;54:688–692.
8.
Gift AG, McCrone SH: Depression in patients with COPD. Heart Lung 1993;22:289–297.
9.
Felker B, Katon W, Hedrick SC, Rasmussen J, McKnight K, McDonnell MB, Fihn SD: The association between depressive symptoms and health status in patients with chronic pulmonary disease. Gen Hosp Psychiatry 2001;23:56–61.
10.
Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, Petersen NJ, Nahas Z, Goodnight-White S: Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000;41:465–471.
11.
Smith EL, Hann DM, Ahles TA, Furstenberg CT, Mitchell TA, Meyer L, Maurer LH, Rigas J, Hammond S: Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage 2001;21:323–329.
12.
Dowson CA, Town GI, Frampton C, Mulder RT: Psychopathology and illness beliefs influence COPD self-management. J Psychosom Res 2004;56:333–340.
13.
Stapleton RD, Nielsen EL, Engelberg RA, Patrick DL, Curtis JR: Association of depression and life-sustaining treatment preferences in patients with COPD. Chest 2005;127:328–334.
14.
Dahlen I, Janson C: Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002;122:1633–1637.
15.
Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J: Mortality after hospitalization for COPD. Chest 2002;121:1441–1448.
16.
Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, McGlynn EA, Ware JE Jr: Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989;262:907–913.
17.
Holland JC, Morrow GR, Schmale A, Derogatis L, Stefanek M, Berenson S, Carpenter PJ, Breitbart W, Feldstein M: A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991;9:1004–1011.
18.
Kunik ME, Braun U, Stanley MA, Wristers K, Molinari V, Stoebner D, Orengo CA: One session cognitive behavioral therapy for elderly patients with chronic obstructive pulmonary disease. Psychol Med 2001;31:717–723.
19.
De Godoy DV, de Godoy R: A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2003;84:1154–1157.
20.
Barrows KA, Jacobs BP: Mind-body medicine: an introduction and review of the literature. Med Clin North Am 2002;86:11–31.
21.
Jorm AF, Christensen H, Griffiths KM, Rodgers B: Effectiveness of complementary and self-help treatments for depression. Med J Aust 2002;176(suppl):S84–96.
22.
Jorm AF, Christensen H, Griffiths KM, Parslow RA, Rodgers B, Blewitt KA: Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust 2004;181(suppl 7):S29–46.
23.
Elsenbruch S, Langhorst J, Popkirowa K, Müller T, Luedtke R, Franken U, Paul A, Spahn G, Michalsen A, Janssen OE, Schedlowski M, Dobos G: Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 2005;74:277–287.
24.
Weiss M, Nordlie JW, Siegel EP: Mindfulness-based stress reduction as an adjunct to outpatient psychotherapy. Psychother Psychosom 2005;74:108–112.
25.
Renfroe KL: Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 1988;17:408–413.
26.
Gift AG, Moore T, Soeken K: Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs Res 1992;41:242–246.
27.
Jacobson E: Progressive Relaxation. Chicago, University of Chicago Press, 1938.
28.
Bernstein DA, Borkovec TD: Progressive Relaxation Training. Champaign, Research Press, 1973.
29.
Bernstein DA, Carlson CR: Progressive relaxation: abbreviated methods; in Lehrer PM, Woolfolk RL (eds): Principles and Practice of Stress Management, ed 2. New York, Guilford Press, 1993, pp 53–87.
30.
Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS: The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomized controlled trial. Support Care Cancer 2002;10:237–246.
31.
Nickel C, Lahmann C, Muehlbacher M, Pedrosa Gil F, Kaplan P, Buschmann W, Tritt K, Kettler C, Bachler E, Egger C, Anvar J, Fartacek R, Loew T, Rother W, Nickel M: Pregnant women with bronchial asthma benefit from progressive muscle relaxation: a randomized, prospective, controlled trial. Psychother Psychosom 2006;75:237–243.
32.
American Thoracic Society: Pulmonary rehabilitation 1999. Am J Respir Crit Care Med 1999;159:1666–1682.
33.
Emery CF, Leatherman NE, Burker EJ, MacIntyre NR: Psychological outcomes of a pulmonary rehabilitation program. Chest 1991;100:613–617.
34.
Garuti G, Cilione C, Dell’Orso D, Gorini P, Lorenzi MC, Totaro L, Cirelli G, Clini E: Impact of comprehensive pulmonary rehabilitation on anxiety and depression in hospitalized COPD patients. Monaldi Arch Chest Dis 2003;59:56–61.
35.
Ries AL, Kaplan RM, Limberg TM, Prewitt LM: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823–832.
36.
Gayle RC, Spitler DL, Karper WB, Jaeger RM, Rice SN: Psychological changes in exercising COPD patients. Int J Rehabil Res 1988;11:335–342.
37.
Guell R, Resqueti V, Sangenis M, Morante F, Martorell B, Casan P, Guyatt GH: Impact of pulmonary rehabilitation on psychosocial morbidity in patients with severe COPD. Chest 2006;129:899–904.
38.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
39.
Herrmann C: International experiences with the Hospital Anxiety and Depression Scale – a review of validation data and clinical results. J Psychosom Res 1997;42:17–41.
40.
Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 2002;52:69–77.
41.
Sloman R: Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs 2002;25:432–435.
42.
Hasson D, Arnetz B, Jelveus L, Edelstam B: A randomized clinical trial of the treatment effects of massage compared to relaxation tape recordings on diffuse long-term pain. Psychother Psychosom 2004;73:17–24.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.